[go: up one dir, main page]

AP2013007070A0 - Imidazo[5,1-f][1,2,4] triazines for the treatment of neurological disorders - Google Patents

Imidazo[5,1-f][1,2,4] triazines for the treatment of neurological disorders

Info

Publication number
AP2013007070A0
AP2013007070A0 AP2013007070A AP2013007070A AP2013007070A0 AP 2013007070 A0 AP2013007070 A0 AP 2013007070A0 AP 2013007070 A AP2013007070 A AP 2013007070A AP 2013007070 A AP2013007070 A AP 2013007070A AP 2013007070 A0 AP2013007070 A0 AP 2013007070A0
Authority
AP
ARIPO
Prior art keywords
triazines
imidazo
treatment
neurological disorders
neurological
Prior art date
Application number
AP2013007070A
Other languages
English (en)
Inventor
Eddie Yang
John Michael Humphrey
Christopher John Helal
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45755439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2013007070(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of AP2013007070A0 publication Critical patent/AP2013007070A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AP2013007070A 2011-02-23 2012-02-09 Imidazo[5,1-f][1,2,4] triazines for the treatment of neurological disorders AP2013007070A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161445617P 2011-02-23 2011-02-23
PCT/IB2012/050589 WO2012114222A1 (en) 2011-02-23 2012-02-09 IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

Publications (1)

Publication Number Publication Date
AP2013007070A0 true AP2013007070A0 (en) 2013-08-31

Family

ID=45755439

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013007070A AP2013007070A0 (en) 2011-02-23 2012-02-09 Imidazo[5,1-f][1,2,4] triazines for the treatment of neurological disorders

Country Status (31)

Country Link
US (2) US8598155B2 (xx)
EP (1) EP2681218A1 (xx)
JP (1) JP5543039B2 (xx)
KR (1) KR101548443B1 (xx)
CN (1) CN103391941A (xx)
AP (1) AP2013007070A0 (xx)
AR (1) AR085304A1 (xx)
AU (1) AU2012221828C1 (xx)
BR (1) BR112013021366A2 (xx)
CA (1) CA2825699A1 (xx)
CL (1) CL2013002125A1 (xx)
CO (1) CO6751271A2 (xx)
CR (1) CR20130371A (xx)
CU (1) CU20130107A7 (xx)
DO (1) DOP2013000194A (xx)
EA (1) EA022586B1 (xx)
EC (1) ECSP13012892A (xx)
GT (1) GT201300206A (xx)
IL (1) IL227716A0 (xx)
MA (1) MA34922B1 (xx)
MX (1) MX2013009684A (xx)
NI (1) NI201300071A (xx)
PE (1) PE20140236A1 (xx)
PH (1) PH12013501556A1 (xx)
SG (1) SG192576A1 (xx)
TN (1) TN2013000349A1 (xx)
TW (1) TWI469983B (xx)
UA (1) UA106692C2 (xx)
UY (1) UY33916A (xx)
WO (1) WO2012114222A1 (xx)
ZA (1) ZA201306348B (xx)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501556A1 (en) * 2011-02-23 2017-10-25 Pfizer IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP6263606B2 (ja) 2013-05-02 2018-01-17 ファイザー・インク Ｐｄｅ１０阻害剤としてのイミダゾ−トリアジン誘導体
WO2015096651A1 (en) 2013-12-23 2015-07-02 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as pde2 inhibitors
US9849132B2 (en) 2014-01-08 2017-12-26 Intra-Cellular Therapies, Inc. Products and pharmaceutical compositions
HRP20212035T1 (hr) * 2014-04-23 2022-04-01 Dart Neuroscience Llc Pripravci koji sadrže supstituirane [1,2,4]triazolo[1,5-a]pirimidin-7-il spojeve kao inhibitore pde2
US10239882B2 (en) 2014-11-05 2019-03-26 Dart Neuroscience (Cayman) Ltd. Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors
AU2015357498B2 (en) 2014-12-06 2019-09-12 Intra-Cellular Therapies, Inc. Organic compounds
HK1243936A1 (zh) 2014-12-06 2018-07-27 Intra-Cellular Therapies, Inc. 有机化合物
CN104525240A (zh) * 2014-12-10 2015-04-22 河北工业大学 硝酸铁作为催化剂在苯与羟胺盐反应一步法制苯胺反应中的应用方法
JP2017538769A (ja) 2014-12-22 2017-12-28 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
TWI713497B (zh) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
WO2016154081A1 (en) 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as pde2 inhibitors
WO2016179059A1 (en) 2015-05-05 2016-11-10 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016209749A1 (en) 2015-06-25 2016-12-29 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
HK1256751A1 (zh) * 2015-11-02 2019-10-04 Janssen Pharmaceutica Nv [1，2，4]三唑并[1，5-a]嘧啶-7-基化合物
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
WO2018065288A1 (de) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft 2-[2-phenyl-1-(sulfonylmethyl)vinyl]-imidazo[4,5-b]pyridin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel im pflanzenschutz
EA039102B1 (ru) 2016-11-02 2021-12-03 Янссен Фармацевтика Нв Соединения [1,2,4]триазоло[1,5-a]пиримидина в качестве ингибиторов pde2
ES2912264T3 (es) 2016-11-02 2022-05-25 Janssen Pharmaceutica Nv Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2
TWI764950B (zh) 2016-11-02 2022-05-21 比利時商健生藥品公司 Ｐｄｅ２抑制劑
KR102515694B1 (ko) 2017-01-10 2023-03-29 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로사이클 유도체
JP7098630B2 (ja) 2017-01-10 2022-07-11 バイエル・アクチエンゲゼルシヤフト 有害生物防除剤としてのヘテロサイクレン誘導体
PL3713572T3 (pl) 2017-11-23 2025-09-22 Oslo University Hospital Hf Leczenie tachykardii
CN108640923A (zh) * 2018-07-09 2018-10-12 湖南天地恒制药有限公司 一种托法替布关键中间体的制备方法
EP3870300B1 (en) * 2018-10-23 2024-07-10 Intra-Cellular Therapies, Inc. Imidazo[1,5-a]pyrazine compounds as pde2 inhibitors
US11492362B1 (en) 2022-02-17 2022-11-08 King Abdulaziz University Pyridine derivatives for the treatment of hyperproliferative diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012113A1 (en) * 1991-12-17 1993-06-24 The Upjohn Company 3-SUBSTITUTED IMIDAZO (1,5-a) AND IMIDAZO (1,5-a)-TRIAZOLO (1,5-c) QUINOXALINES AND QUINAZOLINES WITH CNS ACTIVITY
YU59100A (sh) * 1999-10-11 2003-10-31 Pfizer Inc. Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
DE10230605A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
WO2005041957A1 (en) * 2003-10-29 2005-05-12 Pfizer Products Inc. Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors
AR048518A1 (es) 2004-04-02 2006-05-03 Osi Pharm Inc Inhibidores heterobiciclicos de proteina quinasas sustituidos con anillos 6,6 -biciclicos
AR053090A1 (es) * 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
DE102004038328A1 (de) * 2004-08-06 2006-03-16 Bayer Healthcare Ag Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
ATE479687T1 (de) * 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
EP1874775B1 (en) * 2005-01-05 2012-10-10 Nycomed GmbH Triazolophthalazines as pde2-inhibitors
AP2362A (en) 2005-01-07 2012-02-08 Pfizer Prod Inc Heteroaromatic quinoline compounds and their use as PDE10 inhibitors.
CA2630271C (en) 2005-11-17 2014-04-08 Osi Pharmaceuticals, Inc. Fused bicyclic mtor inhibitors
WO2007087395A2 (en) 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
EP1996193A2 (en) 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
PT2201840E (pt) 2006-09-22 2012-02-14 Pharmacyclics Inc Inibidores da tirosina quinase de bruton
JP2010532756A (ja) 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
US7683575B2 (en) 2007-07-18 2010-03-23 Tesla Motors, Inc. Method and apparatus for identifying and disconnecting short-circuited battery cells within a battery pack
EP2276763A1 (en) 2008-03-19 2011-01-26 OSI Pharmaceuticals, Inc. Mtor inhibitor salt forms
EP2283020B8 (en) 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
JP2012532882A (ja) 2009-07-09 2012-12-20 オーエスアイ・ファーマシューティカルズ，エルエルシー 置換３−アミノ−５−オキソ−４，５−ジヒドロ−［１，２，４］トリアジンのための製法
AU2011269788B2 (en) 2010-02-03 2015-12-10 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazines as c-Met inhibitors
PH12013501556A1 (en) * 2011-02-23 2017-10-25 Pfizer IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

Also Published As

Publication number Publication date
US20140066622A1 (en) 2014-03-06
GT201300206A (es) 2015-02-19
TW201247673A (en) 2012-12-01
TN2013000349A1 (fr) 2015-01-20
AU2012221828B2 (en) 2015-05-28
PE20140236A1 (es) 2014-03-14
DOP2013000194A (es) 2014-01-31
MA34922B1 (fr) 2014-02-01
KR101548443B1 (ko) 2015-08-28
US9200000B2 (en) 2015-12-01
ECSP13012892A (es) 2013-10-31
JP5543039B2 (ja) 2014-07-09
US8598155B2 (en) 2013-12-03
EA022586B1 (ru) 2016-01-29
UA106692C2 (uk) 2014-09-25
AU2012221828C1 (en) 2015-10-01
NZ613373A (en) 2015-04-24
UY33916A (es) 2012-09-28
CN103391941A (zh) 2013-11-13
JP2014506589A (ja) 2014-03-17
NI201300071A (es) 2014-02-12
CA2825699A1 (en) 2012-08-30
CL2013002125A1 (es) 2013-12-20
CU20130107A7 (es) 2013-09-27
PH12013501556A1 (en) 2017-10-25
MX2013009684A (es) 2013-10-28
KR20130132612A (ko) 2013-12-04
ZA201306348B (en) 2014-04-30
EP2681218A1 (en) 2014-01-08
WO2012114222A1 (en) 2012-08-30
US20120214791A1 (en) 2012-08-23
IL227716A0 (en) 2013-09-30
AR085304A1 (es) 2013-09-18
TWI469983B (zh) 2015-01-21
CO6751271A2 (es) 2013-09-16
EA201390971A1 (ru) 2014-02-28
SG192576A1 (en) 2013-09-30
CR20130371A (es) 2013-09-18
BR112013021366A2 (pt) 2016-09-13

Similar Documents

Publication Publication Date Title
ZA201306348B (en) Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders
PT2945632T (pt) Compostos de heterobiciclo-substituído-[1,2,4]triazolo[1,5-c quinazolin-5-amina adequados para o tratamento ou prevenção de distúrbios do sistema nervoso central
IL228681A0 (en) 8-Ethyl-6(aryl)pyrido(3,2-d)pyrimidine-7(8h) - Potencies for the treatment of nervous system disorders and cancer
GB2503852B (en) Compounds for the treatment of neuropsychiatric disorders
ZA201202688B (en) 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
ZA201306038B (en) New compositions for treating neurological disorders
IL235659A0 (en) History of 3, 4 - dihydro -2h - pyrido [1, 2 - a] pyrazine - 1,2,1] 6 converted diones used to treat (among others) Alzheimer's disease
ZA201501677B (en) Mglu2/3 antagonists for the treatment of autistic disorders
SMT201700531T1 (it) Derivati estrogeni per uso nel trattamento di disordini neurologici
HRP20181950T1 (hr) Samidorfan (alks 33) u kombinaciji s buprenorfinom za liječenje depresivnih poremećaja
SI2906209T1 (sl) D-metadon za zdravljenje psihiatričnih simptomov
PL2726470T3 (pl) Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych
IL238415B (en) Compounds for the treatment or prevention of diseases or disorders associated with dysregulation of eif4e
ZA201408060B (en) Compositions and methods for the treatment of neurological disorders
PL2691103T3 (pl) Metoda leczenia zaburzeń skóry
IL244619A0 (en) Pyrido[3-b,4]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders
ZA201408061B (en) Compositions and methods for the treatment of neurological disorders
ZA201400967B (en) A method for predicting clinical benefit in the treatment of neurodevelopmental,neurological or neuropsychiatric disorders
PL395469A1 (pl) Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
HU0900722D0 (en) Compounds for the treatment of neurological disorders
IL228973A (en) Oxymetazoline for the treatment of rectal disorders
HK1194734A (en) 8-ethyl-6-(aryl)pyrido [2,3-d]pyrimidin-7(8h)-ones for the treatment of nervous system disorders and cancer
EP2970118A4 (en) COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS